The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
The Chemours CompanyNYSE: CC
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures growth accelerates
Q2 FY2026 capital expenditures of $93M (cash outflow) rose 116.3% year over year, ahead of the -26.9% change in trailing-twelve-month capital expenditures. Sequentially, it rose 89.8% from the prior quarter. Over 3 fiscal years it compounded at -11.5% a year.
Context
- Capital expenditures amounted to 3.7% of revenue in FY2025, down 2.6 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +116.3% holds above the trailing-twelve-month pace of -26.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (213M) USD
- Year-over-year change
- +40.8%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (213M) | +40.8% |
| FY2024 | 2024-12-31 | (360M) | +2.7% |
| FY2023 | 2023-12-31 | (370M) | -20.5% |
| FY2022 | 2022-12-31 | (307M) | -10.8% |
| FY2021 | 2021-12-31 | (277M) | — |
Capital Expenditures vs competitors
How CC compares with its peers on the latest reported figures
- CC's LTM Jun 2026 capital expenditures of $228M is the 8th largest of the 19 companies compared; the peer median is $181.14M.
- Its year-over-year change of -26.9% is the 14th highest of 19, against a peer median of +11.1%.
- Capital expenditures amounts to 3.9% of revenue for CC, versus a peer median of 5.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.51B | +13.9% | +18.4% | 15.6% | |
| LTM Jun 2026 | $4.87B | -35.7% | -3.1% | 38.7% | |
| LTM Sep 2026 | $1.43B | +173.9% | -0.2% | 4.5% | |
| LTM Jun 2026 | $757M | +10.7% | +17.0% | 4.6% | |
| LTM Sep 2026 | $657M | -36.8% | -3.5% | 5.7% | |
| LTM Jun 2026 | $625M | +15.3% | +5.5% | 6.3% | |
| LTM Sep 2026 | $310.44M | +11.6% | +60.0% | 20.4% | |
| LTM Jun 2026 | $228M | -26.9% | -11.5% | 3.9% | |
| LTM Jun 2026 | $216M | -28.5% | +9.1% | 5.9% | |
| LTM Jun 2026 | $206M | +12.6% | +9.1% | 4.0% | |
| LTM Aug 2026 | $189.33M | +56.4% | +3.1% | 5.3% | |
| LTM Mar 2026 | $172.94M | -13.7% | -11.6% | 9.7% | |
| LTM Jun 2026 | $118.89M | +59.8% | +4.1% | 7.0% | |
| LTM Sep 2026 | $100.4M | +48.7% | +9.2% | 2.9% | |
| LTM Jun 2026 | $71M | -30.4% | -4.6% | 3.9% | |
| LTM Mar 2026 | $60.28M | -20.5% | +6.1% | 7.4% | |
| LTM Jun 2026 | $30.73M | -28.8% | +50.9% | 4.1% | |
| LTM Sep 2026 | $22.23M | -12.6% | +25.1% | 1.1% | |
| LTM Mar 2026 | $18.63M | +13.6% | +53.4% | 16.9% | |
| Peer median (excluding CC) | $181.14M | +11.1% | +7.6% | 5.8% | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 608M | 578M | (238M) | 86M | (386M) |
| Depreciation & Amortization | 317M | 291M | 307M | 301M | 340M |
| Deferred Income Tax | (77M) | 20M | (158M) | (27M) | 64M |
| Stock-Based Compensation | 34M | 27M | 19M | 15M | 21M |
| Change in Working Capital | 21M | (103M) | 620M | (1.05B) | 178M |
| Accounts Receivables | (225M) | 91M | 0 | (152M) | 106M |
| Inventory | (210M) | (294M) | 58M | (146M) | (106M) |
| Accounts Payables | 281M | 105M | (72M) | (9M) | (165M) |
| Other Working Capital | 175M | (5M) | 634M | (745M) | 343M |
| Other Non-Cash Items | (89M) | (58M) | 6M | 44M | 47M |
| Operating Cash Flow | 814M | 755M | 556M | (633M) | 264M |
| Capital Expenditures | (277M) | (307M) | (370M) | (360M) | (213M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 7M |
| Purchases of Investments | (12M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 509M | 23M | 141M | 7M | 0 |
| Investing Cash Flow | 220M | (284M) | (229M) | (353M) | (206M) |
| Debt Repayment | (208M) | (80M) | 393M | 95M | (61M) |
| Common Stock Issued | 0 | 0 | 0 | 9M | 0 |
| Common Stock Repurchased | (173M) | (495M) | (69M) | 0 | (1M) |
| Dividends Paid | (164M) | (154M) | (149M) | (148M) | (78M) |
| Other Financing Activities | (9M) | 43M | 16M | 8M | 14M |
| Financing Cash Flow | (554M) | (686M) | 172M | (36M) | (126M) |
| Effect of Forex Changes | (34M) | (32M) | 4M | (22M) | 27M |
| Net Change in Cash | 446M | (247M) | 503M | (1.04B) | (41M) |
| Free Cash Flow | 537M | 448M | 186M | (993M) | 51M |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.